Clinical Trials Browser

Phase 2 × Disulfides × CNS × Clear all

NCT06325683 2026-03-18

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma

Phase 2 Recruiting

184 enrolled

CNS

Glioblastoma

NCT02971501 2026-03-17

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

Phase 2 Active not recruiting

7 enrolled 9 charts

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03175432 2025-11-03

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Phase 2 Active not recruiting

29 enrolled

CNSDermatologic

Brain Neoplasms, Melanoma

NCT04729959 2025-10-20

Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma

Phase 2 Active not recruiting

59 enrolled

CNS

Astrocytoma, Glioblastoma

NCT02974621 2025-08-03

Cediranib Maleate and Olaparib Compared to Bevacizumab in Treating Patients With Recurrent Glioblastoma

Phase 2 Active not recruiting

70 enrolled 15 charts

CNS

Glioblastoma

NCT01609790 2022-07-21

Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors

Phase 2 Completed

137 enrolled 13 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT02794883 2022-04-18

Tremelimumab and Durvalumab in Combination or Alone in Treating Patients With Recurrent Malignant Glioma

Phase 2 Completed

36 enrolled 13 charts

CNS

Glioblastoma, Glioma

NCT01217437 2021-07-23

Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors

Phase 2 Completed

108 enrolled 14 charts

CNS

Medulloblastoma, Pinealoma, Central Nervous System Neoplasms, Neuroectodermal Tumors, Primitive, Peripheral, Neuroectodermal Tumors, Primitive

NCT00433381 2018-09-17

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

Phase 2 Completed

123 enrolled 16 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00381797 2017-11-28

Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma

Phase 2 Completed

97 enrolled 35 charts

CNS

Familial ependymoma, Medulloblastoma, Oligodendroglioma, Spinal Cord Neoplasms